Capricor Therapeutics, Inc. (CAPR) AI Stock Analysis

Capricor Therapeutics, Inc. is a San Diego-based clinical-stage biotechnology company focused on transformative cell and exosome-based therapies. Its lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that has completed a phase III clinical trial for late-stage Duchenne muscular dystrophy. CAP-1002 is also in phase II trials for cytokine storm associated with SARS-CoV-2. Additionally, Capricor is advancing CAP-2003 through pre-clinical development for trauma-related injuries and conditions, while working on two vaccine candidates to prevent COVID-19. The company collaborates with Lonza Houston, Inc. for clinical manufacturing of CAP-1002 to support scalable production.

Capricor generated revenue of $22.3M in FY2024, down 11.5% from $25.2M in FY2023, following strong expansion from $2.6M in FY2022. Between FY2019 and FY2024, the company recorded a 5-year revenue CAGR of 85.8%. Operating results remain unprofitable, with net income worsening to -$40.5M in FY2024 compared to -$22.3M in FY2023 and -$29.0M in FY2022. Operating margin was -191.1% in FY2024, impacted by R&D expense rising to $50.0M. In the latest quarter ended June 30, 2026, quarterly revenue growth declined 7.9% year-over-year, bringing trailing twelve-month revenue to $11.1M.

As of June 30, 2026, Capricor held $237.9M in cash and short-term investments alongside total debt of $91.0M, resulting in net cash of $146.9M. Total assets stood at $368.7M, supporting a current ratio of 7.35 and a debt-to-equity ratio of 0.37 against shareholders' equity of $246.2M. Free cash flow was -$41.5M in FY2024, while FY2025 capital expenditures were $2.9M. Over five years, the company's share count increased 139.9%.

Capricor holds a market cap of $390.1M and an enterprise value of $396.1M. The stock trades at a forward P/E of 78.7x, well above the 17.3x forward P/E median of its US-listed Healthcare peers. Its price-to-sales ratio stands at 25.1x compared to the peer median of 4.1x. The stock closed at $6.71 on October 16, 2026, down 76.7% year-to-date and 69.0% below its 200-day average. Over one year, the shares returned 8.9%, trailing the S&P 500 (SPY) return of 16.8%.

Capricor is tracked by Wall Street analysts with 3 Strong Buy, 1 Buy, and 6 Hold ratings. The mean price target is $27.00, representing a 302.4% premium over the last close of $6.71. For the current fiscal year ending December 31, 2026, consensus estimates project revenue of $55.7M and an EPS of -$1.45. The company recorded 0 EPS beats over the last 4 quarters. The next earnings date is November 9, 2026.

This page is an AI-written research summary of Capricor Therapeutics, Inc. (CAPR). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CAPR income statement, CAPR balance sheet, CAPR key metrics, CAPR analyst forecast, CAPR chart. See the CAPR stock overview for the latest quote and news.